Stockscreener 앱 받기
46.37
0.31%
0.165
시간 외 거래:
46.23
-0.135
-0.29%
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
Bristol-Myers Squibb: Hold Rating Amid Slower Cobenfy Launch and Fair Valuation - TipRanks
Aug Wrap: Will Bristol Myers Squibb Company Equity Right stock hit new highs in YEARWall Street Watch & AI Enhanced Trade Execution Alerts - خودرو بانک
Biokin/BMS, Genfleet/Verastem’s Drug Candidates Impress At WCLC - insights.citeline.com
Ascent Group LLC Buys 8,721 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Promising Lung Cancer Trial Results Could Be a Game Changer for Bristol-Myers Squibb (BMY) - simplywall.st
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $1.38 Billion Position in Bristol Myers Squibb Company $BMY - MarketBeat
Flputnam Lifts Stake in Bristol-Myers Squibb Company (BMY) by 52% - MSN
BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains? - Yahoo Finance
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Stance Capital LLC Purchases 39,165 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Graham Capital Management L.P. Invests $568,000 in Bristol Myers Squibb Company $BMY - MarketBeat
BMO Capital Maintains a Hold on Bristol-Myers Squibb Company (BMY) - Insider Monkey
Bristol Myers Squibb, BioNTech Announce Positive Interim Data from Phase 2 Trial of Pumitamig in Lung Cancer - Insider Monkey
Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight - GlobeNewswire Inc.
October 31st Options Now Available For Bristol Myers Squibb (BMY) - Nasdaq
Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold? - Yahoo Finance
Bristol-Myers Squibb (BMY): Assessing Valuation After New Pipeline Updates and Growth Strategy Reveal - Yahoo Finance
Bristol Myers Squibb Company $BMY Shares Acquired by Bayforest Capital Ltd - MarketBeat
United Services Automobile Association Has $12.60 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to Know - Yahoo Finance
BioNTech and Bristol-Myers Squibb Partner to Advance Cancer Therapy - MSN
BMS, BioNTech Post Geographically Consistent Mid-Stage PD-L1/VEGF Data in SCLC - BioSpace
WCLC25: BioNTech, BMS tout second readout for PD-L1/VEGF-A in SCLC - FirstWord Pharma
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy - Benzinga
BioNTech and Bristol Myers Squibb amend partnership for BNT327 with $1.5 billion upfront payment - Investing.com Canada
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity - The Manila Times
BioNTech, Bristol Myers present interim data from a Phase 2 pumitamig trial - TipRanks
BioNTech and Bristol Myers Squibb Announce Encouraging Phase 2 Data for Pumitamig Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer - Quiver Quantitative
BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial - Reuters
BioNTech, BMS tout first global data for PD-L1xVEGF bispecific in small cell lung cancer, set phase 3 dose - Fierce Biotech
Bristol-Myers Squibb at Morgan Stanley Conference: Strategic Insights - Investing.com
Hold Recommendation for Bristol-Myers Squibb Due to Cobenfy’s Modest Growth and Revenue Projections - TipRanks
Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point (NYSE:BMY) - Seeking Alpha
Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology Leadership (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb Company $BMY Shares Purchased by Baird Financial Group Inc. - MarketBeat
What is Bristol Myers Squibb Company s debt to equity ratioWeekly Earnings Recap & Free Accurate Trade Setup Notifications - خودرو بانک
Is Bristol-Myers Squibb (BMY) a Value Trap or a Sleeping Giant in Biopharma? - AInvest
Short interest data insights for Bristol Myers Squibb Company Equity RightJuly 2025 Catalysts & High Accuracy Swing Trade Signals - Newser
Using data tools to time your Bristol Myers Squibb Company exitGap Down & Fast Entry and Exit Trade Plans - Newser
Bravehart, a stealthy startup, looks to China to challenge Bristol Myers heart drug - BioPharma Dive
Independent research - Bristol Myers Squibb
Split 3rd Circ. Rejects Janssen, Bristol Myers Pricing Appeal - Law360
Top chart patterns to watch in Bristol Myers Squibb CompanyMarket Growth Summary & AI Driven Stock Price Forecasts - Newser
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields - Benzinga
J&J, Bristol Myers Lose Bid to Revive Suit Over Drug Price Talks - Bloomberg Law News
How Is Bristol-Myers’ Stock Performance Compared To Other Pharma Stocks? - Barchart.com
Mubadala Investment Co PJSC Purchases New Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb: Not As Cheap As It Might Seem (NYSE:BMY) - Seeking Alpha
Gilead starts building manufacturing hub under $32 billion planned US investments - Reuters
Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE? - Yahoo Finance
Combining machine learning predictions for Bristol Myers Squibb CompanyPortfolio Update Report & Expert Curated Trade Ideas - Newser
Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.
0.81%
0.44%
자본화:
|
볼륨(24시간):